Divisions of Immunology and Allergy, Lausanne University Hospital, Lausanne, Switzerland.
Division of Rheumatology, Evaggelismos General Hospital, Athens, Greece.
Clin Immunol. 2019 Jul;204:57-63. doi: 10.1016/j.clim.2018.11.001. Epub 2018 Nov 8.
Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease characterized by a breakdown in immune tolerance leading to the development of auto-reactive lymphocytes and autoantibodies. Recent findings have provided new insight on the role of the signaling lymphocytic activation molecule family (SLAMF) receptors, a group of nine co-regulatory molecules involved in the activation of hematopoietic cells, and their downstream protein SLAM-associated protein (SAP), into the pathogenesis of SLE. This review summarizes the current knowledge on SLAMF in human SLE immunopathogenesis, and the importance of SLAMF molecules as new therapeutic targets.
系统性红斑狼疮(SLE)是一种多因素自身免疫性疾病,其特征是免疫耐受的破坏,导致自身反应性淋巴细胞和自身抗体的产生。最近的研究结果提供了新的见解,表明信号淋巴细胞激活分子家族(SLAMF)受体在发病机制中的作用,这是一组参与造血细胞激活的九个共调节分子,以及它们的下游蛋白 SLAM 相关蛋白(SAP)。本文综述了 SLAMF 在人类 SLE 免疫发病机制中的最新知识,以及 SLAMF 分子作为新的治疗靶点的重要性。